Table 1.

Age, gendersex, initial symptoms, primary symptoms, CSF testing, MRI, and mRS scores of patients with anti-DPPX encephalitis.

Characteristics	N (%)
Sex Male Female	9/14 64.3% 5/14 35.7%
Age, year Mean (range)	45.93 (11–72)
Initial symptoms Gastrointestinal symptoms Dizziness Ataxia Seizures Cognitive impairment Fever Hallucinations Headache	5/14 35.7% 4/14 28.6% 3/14 21.4% 2/14 14.3% 2/14 14.3% 2/14 14.3% 2/14 14.3% 1/14 7.1%
Primary symptoms Cognitive impairment CNS hyperexcitability Myoclonus Seizures Limb convulsions Gastrointestinal symptoms Psychiatric abnormalities Hallucinations Dizziness Ataxia Weight loss Consciousness changes Nystagmus Sleep disturbances Bulbar dysfunction Weakness in lower limbs	7/14 50.0% 6/14 42.9% 3/6 2/6 1/6 5/14 35.7% 5/14 35.7% 4/14 28.6% 4/14 28.6% 3/14 21.4% 2/14 14.3% 2/14 14.3% 2/14 14.3% 2/14 14.3% 1/14 7.1% 1/14 7.1%
CSF testing Normal Protein >500 mg/L Chloride >130 mmol/L Glucose >4.5 mmol/L Pleocytosis	9/14 64.3% 2/14 14.3% 2/14 14.3% 1/14 7.1% 0/14 0.0%
MRI Normal or nonspecific changes Atrophy or swollen in the hippocampus Cerebellar atrophy Frontotemporal abnormal signals	8/14 57.1% 3/14 21.4% 2/14 14.3% 1/14 7.1%
mRS at admission 2 3 4 5	1/14 7.1% 6/14 42.9% 5/14 35.7% 2/14 14.3%
mRS at discharge 0 1 2 4	1/14 7.1% 7/14 50.0% 5/14 35.7% 1/14 7.1%
mRS at follow-up 0 1 2 5	4/14 28.6% 5/14 35.7% 2/14 14.3% 3/14 21.4%

CSF, cerebrospinal fluid; MRI, magnetic resonance imaging; mRS, modified Rankin Scale; CNS, central nervous system.